# Yokohama City University Medical Center

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/yokohama-city-university-medical-center/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 40.8 |
| Citations | 359,479 |
| City | Yokohama |
| Country | JP |
| Description | Yokohama City University Medical Center is a research organisation in Yokohama, JP. OpenAlex records 7,349 works and 359,479 citations for it. 1,548 researchers list it as their most recent affiliation. |
| Homepage | http://www.yokohama-cu.ac.jp/urahp/ |
| OpenAlex ID | https://openalex.org/I2802180866 |
| Researchers | 1,548 |
| ROR ID | https://ror.org/03k95ve17 |
| Type | healthcare |
| Wikidata ID | https://www.wikidata.org/wiki/Q11543074 |
| Works | 7,349 |

## University papers

Showing 12 of 62.

- [Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/ramucirumab-after-sorafenib-in-patients-with-advanced-hepatocellular-carcinoma/)
- [Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME](https://scholariq.org/papers/recent-advances-in-2d-and-3d-in-vitro-systems-using-primary-hepatocytes/)
- [Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study](https://scholariq.org/papers/randomized-phase-iii-study-of-gemcitabine-plus-s-1-s-1-alone-or-gemcitabine/)
- [JCS 2018 Guideline on Diagnosis and Treatment of Acute Coronary Syndrome](https://scholariq.org/papers/jcs-2018-guideline-on-diagnosis-and-treatment-of-acute-coronary-syndrome/)
- [WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia](https://scholariq.org/papers/wt1-as-a-new-prognostic-factor-and-a-new-marker-for-the-detection-of-minimal/)
- [Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study](https://scholariq.org/papers/atezolizumab-with-or-without-bevacizumab-in-unresectable-hepatocellular/)
- [Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial](https://scholariq.org/papers/atezolizumab-plus-bevacizumab-versus-active-surveillance-in-patients-with/)
- [Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials](https://scholariq.org/papers/human-atrial-natriuretic-peptide-and-nicorandil-as-adjuncts-to-reperfusion/)
- [Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial](https://scholariq.org/papers/lenvatinib-plus-pembrolizumab-versus-lenvatinib-plus-placebo-for-advanced/)
- [Effect of Intensive Statin Therapy on Regression of Coronary Atherosclerosis in Patients With Acute Coronary Syndrome](https://scholariq.org/papers/effect-of-intensive-statin-therapy-on-regression-of-coronary-atherosclerosis-in/)
- [Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial](https://scholariq.org/papers/combination-gemcitabine-plus-s-1-versus-gemcitabine-plus-cisplatin-for-advanced/)
- [Midterm outcomes in patients with intermediate‐sized hepatocellular carcinoma](https://scholariq.org/papers/midterm-outcomes-in-patients-with-intermediate-sized-hepatocellular-carcinoma/)

## University researchers

- [Manabu Morimoto](https://scholariq.org/researchers/manabu-morimoto/)
- [Kazuya Sugimori](https://scholariq.org/researchers/kazuya-sugimori/)
- [Iwaho Kikuchi](https://scholariq.org/researchers/iwaho-kikuchi/)
- [Haruo Miwa](https://scholariq.org/researchers/haruo-miwa/)
- [Daiki Ueno](https://scholariq.org/researchers/daiki-ueno/)
- [Yoshimasa Suzuki](https://scholariq.org/researchers/yoshimasa-suzuki/)

## University top topics

Showing 8 of 25.

- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)
- [Coronary Interventions and Diagnostics](https://scholariq.org/topics/coronary-interventions-and-diagnostics/)
- [Cardiac Imaging and Diagnostics](https://scholariq.org/topics/cardiac-imaging-and-diagnostics/)
- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)
- [Colorectal Cancer Surgical Treatments](https://scholariq.org/topics/colorectal-cancer-surgical-treatments/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Acute Myocardial Infarction Research](https://scholariq.org/topics/acute-myocardial-infarction-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.